Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification

World Journal of Gastroenterology

Volumn 19, Issue 1, 2013, Pages 57-64

  Zelber Sagi, Shira ^a,b   Webb, Muriel ^a   Assy, Nimer ^c   Blendis, Laurie ^a   Yeshua, Hanny ^a   Leshno, Moshe ^a,d   Ratziu, Vlad ^e   Halpern, Zamir ^a,d   Oren, Ran ^a,d   Santo, Erwin ^a,d  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b UNIVERSITY OF HAIFA   (Israel)

^c BAR ILAN UNIVERSITY   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

^e SORBONNE UNIVERSITÉ   (France)

Author keywords

Agreement; Fatty liver index; Hepatorenal ultrasound index; Screening; Sensitivity; Specificity; Steatosis; Steatotest

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; ECHOGRAPHY; FATTY LIVER; FATTY LIVER INDEX; FEMALE; HEPATORENAL ULTRASOUND INDEX; HUMAN; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; PREDICTIVE VALUE; PREVALENCE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STEATO TEST; VALIDATION PROCESS; WAIST CIRCUMFERENCE;

EID: 84873661057     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i1.57     Document Type: Article

References (52)

1. Caldwell S, Argo C. The natural history of non-alcoholic fatty liver disease. Dig Dis 2010; 28: 162-168[PMID: 20460906]
2. Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G, Adams LA, Charatcharoenwitthaya P, Topping JH, Bugianesi E, Day CP, George J. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011; 54: 1208-1216[PMID: 21688282 DOI: 10.1002/hep.24491]
3. Bellentani S, Saccoccio G, Masutti F, Crocè LS, Brandi G, Sasso F, Cristanini G, Tiribelli C. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112-117[PMID: 10644271]
4. Bedogni G, Bellentani S. Fatty liver: how frequent is it and why? Ann Hepatol 2004; 3: 63-65 [PMID: 15257248]
5. Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int 2006; 26: 856-863 [PMID: 16911469]
6. Sung KC, Ryan MC, Wilson AM. The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects. Atherosclerosis 2009; 203: 581-586 [PMID: 18774133]
7. Stefan N, Kantartzis K, Häring HU. Causes and metabolic consequences of Fatty liver. Endocr Rev 2008; 29: 939-960 [PMID: 18723451]
8. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ 2005; 172: 899-905 [PMID: 15795412]
9. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F, Poynard T. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-1906 [PMID: 15940625]
10. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-750 [PMID: 12198701]
11. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol 2003; 15: 539-543 [PMID: 12702913 DOI: 10.1097/01.meg.0000059112.41030.2e]
12. Siegelman ES, Rosen MA. Imaging of hepatic steatosis. Semin Liver Dis 2001; 21: 71-80 [PMID: 11296698]
13. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6: 33 [PMID: 17081293]
14. Webb M, Yeshua H, Zelber-Sagi S, Santo E, Brazowski E, Halpern Z, Oren R. Diagnostic value of a computerized hepatorenal index for sonographic quantification of liver steatosis. AJR Am J Roentgenol 2009; 192: 909-914 [PMID: 19304694]
15. Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D, Capron D, Abella A, Massard J, Ngo Y, Munteanu M, Mercadier A, Manns M, Albrecht J. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005; 4: 10 [PMID: 16375767]
16. Nitzan Kaluski D, Goldsmith R, Chinitz A, Ben Arie-Magled O, Mayer C, Green M. First National Health and Nutrition Survey, Part I 1999-2001. Jerusalem, Israel: Israel Center for Disease Control, 2003
17. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Zvibel I, Goldiner I, Blendis L, Halpern Z, Oren R. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatology 2008; 48: 1791-1798 [PMID: 18972405 DOI: 10.1002/hep.22525]
18. Imbert-Bismut F, Messous D, Thibault V, Myers RB, Piton A, Thabut D, Devers L, Hainque B, Mercadier A, Poynard T. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med 2004; 42: 323-333 [PMID: 15080567 DOI: 10.1515/CCLM.2004.058]
19. Gore RM. Diffuse liver disease. In: Gore R, Levine MS, Laufer I, editors. Textbook of Gastrointestinal Radiology. Philadelphia: Saunders, 1994: 1968-2017
20. Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R. NAFLD and hyperinsulinemia are major determinants of serum ferritin levels. J Hepatol 2007; 46: 700-707 [PMID: 17150278]
21. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174 [PMID: 843571]
22. Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, Chim AM, Yu J, Sung JJ, Chan HL. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59: 969-974 [PMID: 20581244]
23. Sung KC, Kim SH. Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes. J Clin Endocrinol Metab 2011; 96: 1093-1097 [PMID: 21252243]
24. Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol 2007; 22: 1086-1091 [PMID: 17608855]
25. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43: 617-649 [PMID: 21039302 DOI: 10.3109/07853890.2010.518623]
26. Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, Zenari L, Falezza G. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005; 54: 3541-3546 [PMID: 16306373]
27. Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, Zoli M, Marchesini G. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005; 42: 473-480 [PMID: 15981216 DOI: 10.1002/hep.20781]
28. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121 [PMID: 16012941]
29. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of nonalcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009; 58: 1538-1544 [PMID: 19625277]
30. David K, Kowdley KV, Unalp A, Kanwal F, Brunt EM, Schwimmer JB. Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009; 49: 1904-1912 [PMID: 19434741 DOI: 10.1002/hep.22868]
31. Newton JL, Jones DE, Henderson E, Kane L, Wilton K, Burt AD, Day CP. Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance. Gut 2008; 57: 807-813 [PMID: 18270241]
32. Elwing JE, Lustman PJ, Wang HL, Clouse RE. Depression, anxiety, and nonalcoholic steatohepatitis. Psychosom Med 1991; 68: 563-569 [PMID: 16868265]
33. Baumeister SE, Völzke H, Marschall P, John U, Schmidt CO, Flessa S, Alte D. Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation. Gastroenterology 2008; 134: 85-94 [PMID: 18005961]
34. Lassailly G, Caiazzo R, Hollebecque A, Buob D, Leteurtre E, Arnalsteen L, Louvet A, Pigeyre M, Raverdy V, Verkindt H, Six MF, Eberle C, Patrice A, Dharancy S, Romon M, Pattou F, Mathurin P. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity. Eur J Gastroenterol Hepatol 2011; 23: 499-506 [PMID: 21499110 DOI: 10.1097/ MEG.0b013e3283464111]
35. Neuman G, Sagi R, Shalitin S, Reif S. Serum inflammatory markers in overweight children and adolescents with nonalcoholic fatty liver disease. Isr Med Assoc J 2010; 12: 410-415 [PMID: 20862821]
36. Soder RB, Baldisserotto M, Duval da Silva V. Computerassisted ultrasound analysis of liver echogenicity in obese and normal-weight children. AJR Am J Roentgenol 2009; 192: W201-W205 [PMID: 19380523]
37. Ratziu V, Giral P, Munteanu M, Messous D, Mercadier A, Bernard M, Morra R, Imbert-Bismut F, Bruckert E, Poynard T. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia. Aliment Pharmacol Ther 2007; 25: 207-218 [PMID: 17229244]
38. Rubio A, Monpoux F, Huguon E, Truchi R, Triolo V, Rosenthal-Allieri MA, Deville A, Rosenthal E, Boutté P, Tran A. Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children. J Pediatr Gastroenterol Nutr 2009; 49: 599-606 [PMID: 19668009 DOI: 10.1097/ MPG.0b013e3181a15b72]
39. Friedrich-Rust M, Müller C, Winckler A, Kriener S, Herrmann E, Holtmeier J, Poynard T, Vogl TJ, Zeuzem S, Hammerstingl R, Sarrazin C. Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers. J Clin Gastroenterol 2010; 44: 58-65 [PMID: 19581812 DOI: 10.1097/MCG.0b013e3181a84b8d]
40. Gastaldelli A, Kozakova M, Højlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, Balkau B. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009; 49: 1537-1544 [PMID: 19291789 DOI: 10.1002/ hep.22845]
41. Balkau B, Lange C, Vol S, Fumeron F, Bonnet F. Nineyear incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study. BMC Gastroenterol 2010; 10: 56 [PMID: 20529259]
42. Kim CH, Park JY, Lee KU, Kim JH, Kim HK. Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults. Diabet Med 2008; 25: 476-481 [PMID: 18346164]
43. Calori G, Lattuada G, Ragogna F, Garancini MP, Crosignani P, Villa M, Bosi E, Ruotolo G, Piemonti L, Perseghin G. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology 2011; 54: 145-152 [PMID: 21488080 DOI: 10.1002/hep.24356]
44. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395 [PMID: 15565570 DOI: 10.1002/hep.20466]
45. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44-52 [PMID: 15895401 DOI: 10.1002/ hep.20734]
46. Fan JG, Zhu J, Li XJ, Chen L, Li L, Dai F, Li F, Chen SY. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 2005; 43: 508-514 [PMID: 16006003]
47. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1705-1725 [PMID: 12404245]
48. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, Clark JM. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a metaanalysis. Hepatology 2011; 54: 1082-1090 [PMID: 21618575 DOI: 10.1002/hep.24452]
49. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term followup of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873 [PMID: 17006923 DOI: 10.1002/ hep.21327]
50. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, Younossi ZM. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7: 234-238 [PMID: 19049831]
51. Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, Ratziu V, McCullough A. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011; 54: 344-353 [PMID: 21520200 DOI: 10.1002/hep.24376]
52. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53: 372-384 [PMID: 20494470]